GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results
Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors.

Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.
Advanced Solid Tumor|Non-Small Cell Lung Cancer|Pancreatic Cancer|Colorectal Cancer|Head and Neck Neoplasm
DRUG: GH21 Capsule
Determination of Maximum Tolerated Dose (MTD) of GH21., MTD is the highest dose of a treatment that does not cause unacceptable side effects., 28 Days|Characterize the Safety of GH21, Number of participants with treatment-emergent adverse events and serious AEs., Approximately 3 years
Objective Response Rate (ORR), Based on assessment of radiographic imaging per RECIST version 1.1, Approximately 3 years|Disease Control Rate (DCR), Based on assessment of radiographic imaging per RECIST version 1.1, Approximately 3 years|Duration of Response (DOR), Based on assessment of radiographic imaging per RECIST version 1.1, Approximately 3 years|Progression-Free Survival (PFS), Based on assessment of radiographic imaging per RECIST version 1.1, Approximately 3 years|PD of GH21, Change of phosphorylated ERK, Approximately 3 years|Cmax, The maximum or "peak" concentration of GH21 observed after administration, Approximately 3 years|Tmax, The time to peak concentration of GH21, Approximately 3 years|T1/2, Half-life of GH21, Approximately 3 years
Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors.

Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.